Genomics
Academic CDMOs, like commercial ones, play critical role in CGT sector
The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility. Read More
Induced pluripotent stem cell technology offers potential treatment for hair loss
Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells. Read More
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia
Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Antion Biosciences takes allogeneic approach to therapies with microRNA technology
Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs. Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers
In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies. Read More
Cell and gene therapy sector is in midst of an ‘industrial revolution’: Miguel Forte
Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector. Read More
Platform enables precise, efficient delivery of genetic medicines in vivo
Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform. Read More
Manufacturing remains big challenge for cell and gene therapy industry
Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry. Read More
Gene editing advances continue a pace, but progress is still early: panel
With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are looking forward to other near- and longer-term breakthrough technologies on the horizon. Read More
Roadblocks continue to hamper CGT companies as they look to commercialize their products
The cell and gene therapy (CGT) sector will continue to face investment and regulator challenges in the near term. That’s the consensus of companies in the space who participated in a workshop at this week’s Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter